Improved survival achieved by HIV-infected patients has complicated their medical care, as increasing numbers of comorbidities have led to polypharmacy and a higher risk of drug–drug interactions. Here, evidence is provided that weight-loss drugs should be used with caution in HIV-infected patients treated with lipophilic antiretroviral drugs because of the risk of virologic failure. This is particularly relevant considering that these agents are available on the market as over-the-counter medications, thus escaping the control of the physician.
Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution? / D. Cattaneo, A. Giacomelli, C. Gervasoni. - In: OBESITY. - ISSN 1930-7381. - 26:8(2018 Aug), pp. 1251-1252. [10.1002/oby.22240]
Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?
A. GiacomelliSecondo
;
2018
Abstract
Improved survival achieved by HIV-infected patients has complicated their medical care, as increasing numbers of comorbidities have led to polypharmacy and a higher risk of drug–drug interactions. Here, evidence is provided that weight-loss drugs should be used with caution in HIV-infected patients treated with lipophilic antiretroviral drugs because of the risk of virologic failure. This is particularly relevant considering that these agents are available on the market as over-the-counter medications, thus escaping the control of the physician.File | Dimensione | Formato | |
---|---|---|---|
Cattaneo_et_al-2018-Obesity (1).pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
95.31 kB
Formato
Adobe PDF
|
95.31 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.